EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Switching from paliperidone palmitate 3-monthly long-acting injection to oral aripiprazole in a pregnant woman with schizophrenia: a case report and short review

Carolina Pinci, Emanuela Bianciardi, Irene Sferra, Giulia Castellani, Riccardo Santini, Alberto Siracusano, Cinzia Niolu

Rivista di Psichiatria · 2024

DOI: 10.1708/4259.42361 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Rivista di Psichiatria, 2024. Verfasst von Carolina Pinci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Hauptthemen laut MEDLINE: Aripiprazole, Paliperidone Palmitate, Antipsychotic Agents, Schizophrenia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment with long-acting injection (LAI) antipsychotics, such as paliperidone palmitate, has improved the quality of life in terms of symptoms and prevention of relapses in patients with schizophrenia. Although there are plenty of evidences about the efficacy and safety of paliperidone palmitate 3-monthly injection (PP3M) in adults with schizophrenia, literature appears lacking about the use of LAIs during pregnancy. We hereby describe the clinical case of a pregnant woman affected by schizophrenia (DSM-5-TR), taking pharmacological treatment of PP3M. Considering the inadequate evidence regarding the use of PP3M in pregnancy in agreement with the patient, we switched PP3M to an oral therapy with aripiprazole. The switch to oral aripiprazole allowed the patient to improve her sense of autonomy and strengthen the therapeutic relationship. To our knowledge, this is the first case report monitoring an entire pregnancy of a women affected by schizophrenia in treatment with PP3M injection and oral aripiprazole. No obstetrical or fetal complications were reported. As the research in this field is very demanding, it would be precipitous to derive final conclusions from the current case report, but we hope to build a growing number of data that would allow us to make more appropriate and safe therapeutic choices in such a vulnerable phase as the peripartum.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazolePaliperidone PalmitateAntipsychotic AgentsSchizophreniaDelayed-Action PreparationsPregnancy ComplicationsHumansFemalePregnancyAdultAdministration, OralDrug SubstitutionInjections, Intramuscular

Substanzen

AripiprazolePaliperidone PalmitateAntipsychotic AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Zitieren

APA

Pinci, C., Bianciardi, E., Sferra, I., Castellani, G., Santini, R., Siracusano, A., & Niolu, C. (2024). Switching from paliperidone palmitate 3-monthly long-acting injection to oral aripiprazole in a pregnant woman with schizophrenia: a case report and short review. Rivista di Psichiatria. https://doi.org/10.1708/4259.42361

Vancouver

Pinci C, Bianciardi E, Sferra I, Castellani G, Santini R, Siracusano A, et al. Switching from paliperidone palmitate 3-monthly long-acting injection to oral aripiprazole in a pregnant woman with schizophrenia: a case report and short review. Rivista di Psichiatria. 2024. doi:10.1708/4259.42361

BibTeX
@article{Pinci2024,
  author = {Pinci, Carolina and Bianciardi, Emanuela and Sferra, Irene and Castellani, Giulia and Santini, Riccardo and Siracusano, Alberto and Niolu, Cinzia},
  title = {Switching from paliperidone palmitate 3-monthly long-acting injection to oral aripiprazole in a pregnant woman with schizophrenia: a case report and short review},
  journal = {Rivista di Psichiatria},
  year = {2024},
  doi = {10.1708/4259.42361}
}
Kostenlos starten →